People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
Because of the risks of serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, and misuse, to facilitate safe and appropriate use, SPRAVATO ® is only ...
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
The U.S. Food and Drug Administration has expanded its approval of Spravato, an antidepressant nasal spray. The drug is now ...